Autolus Therapeutics (NASDAQ:AUTL) Posts Quarterly Earnings Results, Meets Estimates

Autolus Therapeutics (NASDAQ:AUTL) announced its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21), FiscalAI reports. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. The business had revenue of $41.24 million for the quarter, compared to the consensus estimate of $39.54 million.

Here are the key takeaways from Autolus Therapeutics’ conference call:

• AUCATZYL revenue accelerated: Q3 net product revenue rose 95% year over year to $41.2 million, and Autolus now expects full-year 2026 revenue of at least $150 million, above its prior guidance range.
• Commercial reach expanded ahead of plan, with 90 U.S. centers authorized against an 80-center goal and 18 centers authorized in the U.K.; management said the U.K. launch is going well.
• Gross margin improved to 57% in Q3 and 44% year to date. Management attributed the gains to higher production volumes and manufacturing efficiencies, saying the company expects continued gradual improvement.
• Cash, cash equivalents, and marketable securities totaled $248.4 million at quarter-end; the company expects funding into Q2 2028, assuming anticipated AUCATZYL sales and $25 million from the second tranche of its credit facility. Q3 net loss was $55.1 million.
• Autolus moved its first BOBCAT progressive MS data presentation to October 2027 to allow longer follow-up, citing expert feedback that at least 12 months is needed to assess clinical outcomes. Management said the study remains on track, but the data update will come later than previously anticipated.

Autolus Therapeutics Stock Down 4.9%

Shares of NASDAQ AUTL traded down $0.07 during mid-day trading on Tuesday, reaching $1.25. 3,900,273 shares of the company were exchanged, compared to its average volume of 1,834,241. Autolus Therapeutics has a 1 year low of $1.12 and a 1 year high of $2.58. The firm has a 50-day moving average of $1.78 and a 200 day moving average of $1.66. The stock has a market cap of $334.03 million, a price-to-earnings ratio of -1.18 and a beta of 2.32. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AUTL shares. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. HC Wainwright started coverage on shares of Autolus Therapeutics in a report on Monday, November 2nd. They issued a “buy” rating on the stock. Finally, Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Autolus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.00.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.